Join us for our “meet the expert” panel discussion for Corbus Pharmaceuticals focusing  their Nectin-4 targeting ADC (CRB-701) and the diverse indications relevant to its development. Discussion will focus on unmet needs, Nectin-4 biology and the features of differentiation in the design of CRB-701 relative to enfortumab vedotin (PADCEV). The panel comprises 3 medical oncologists covering GU, H&N and NSCLC tumors as well as a translational expert who will provide their insights and answer questions from the audience. The panel will be moderated by Rachael Brake, PhD, CSO of Corbus.

We welcome the opportunity to consider questions for the panel prior to the event please email questions to  questions@lifesciadvisors.com.